194882712 - 1_855g8scs - PID 1851201
    
    
      
    
  

  
    
        Hi I am Ted Dixon with
        your INK Morning Report
Preview
        for October 28th:
        Insiders bet on big Bausch
Health
        as it sets to get smaller.
        We close off our
        Canadian Healthcare
mini-series by visiting
        our top-ranked big cap
name
        in the group Bausch Health
Companies.
        Bausch has a plan to split
the company into
        three: Bausch and Lomb - a
fully integrated,
        pure play eye-health
company,
        Solta Medical focused
        on medical aesthetic
devices,
        and Bausch Pharma - a
        diversified
        international
pharmaceutical company.
        The stock has responded
positively to
        the company's evolving
        road map to essentially
        get smaller up the stock
is
        about 47% over the past
year.
        In addition, earlier this
year,
        the company came to an
agreement with
        investor activist Carl
Icahn
        which saw the Icahn group
        get two seats on the board
which are filled
        by Brett Icahn and Steven
Miller.
        Their addition adds to
        an already strong culture
        of insider commitment at
        the firm as demonstrated
by
        rising insider ownership
over the past year.
        In terms of financial
results,
        the pandemic has served as
        a headwind for sales but
        following a strong Q2 of
this year,
        free cash flow is up
notably.
        In the months ahead,
        the Healthcare sector may
be seen
        as offering a form of
        protection from fears
associated
        with tighter central bank
policies.
        If so, Bausch may also
        provide the added comfort
of
        a well-defined road map in
terms of how
        it is striving to generate
shareholder value.
        That is all for today
        and thanks for dropping
by.
        Click on the notify button
        under this video on
        INK Ultra Money to be
notified when
        we have our next preview
available.
        Members can also find
        our full report under this
video.
        Finally, don’t forget to
follow us on
        Twitter @inkresearch and
please join us
        again tomorrow as we let
        the insiders guide us
        to opportunity this fall.
        This is not a
recommendation to
        buy or sell securities and
        nothing in this video or
        in INK reports should be
considered
        financial advice
information is for
        educational purposes INK
employees may
        hold an interest in any
stock
        mentioned in our videos or
in our reports.